Provera Contraindications and Dosing for Delaying Menstruation
Absolute Contraindications
Provera (medroxyprogesterone acetate) is absolutely contraindicated in the following conditions: 1
- Undiagnosed abnormal genital bleeding
- Known, suspected, or history of breast cancer
- Known or suspected estrogen- or progesterone-dependent neoplasia
- Active deep vein thrombosis (DVT), pulmonary embolism (PE), or history of these conditions
- Active arterial thromboembolic disease (stroke, myocardial infarction) or history of these conditions
- Known anaphylactic reaction or angioedema to medroxyprogesterone acetate
- Known liver impairment or disease
- Known or suspected pregnancy 1
Additional cardiovascular contraindications include history of stroke, myocardial infarction, pulmonary embolism, and active smoking combined with other cardiovascular risk factors. 2
Dosing Regimens for Delaying Menstruation
Standard Dosing for Menstrual Manipulation
For delaying menstruation, Provera may be given at 5–10 mg daily for 5–10 days, starting approximately 5 days before the expected onset of menses. 1 The FDA-approved dosing for abnormal uterine bleeding is 5–10 mg daily for 5–10 days, with 10 mg daily for 10 days producing optimal secretory transformation of the endometrium. 1
To delay a period, begin Provera 3–5 days before the anticipated menstrual start date and continue through the event or time period during which menstruation should be avoided. 1 Progestin withdrawal bleeding typically occurs within 3–7 days after discontinuing therapy. 1
Alternative Approach: Combined Oral Contraceptives Are Preferred
Combined oral contraceptives containing 30–35 µg ethinyl estradiol are the preferred first-line method for delaying menstruation, not progestin-only medications like Provera. 3 Patients can skip the placebo pills and immediately start a new pack of active pills to delay menstruation, avoiding the hormone-free interval. 3
If breakthrough bleeding occurs with extended COC regimens, a 3–4 day hormone-free interval can temporarily induce bleeding, but this should not be done during the first 21 days of use and not more than once per month. 4, 3
Important Limitation
Neither norethindrone nor combined oral contraceptives used for menstrual delay should be relied upon as contraception unless the patient has been using them continuously. 3 Similarly, Provera used solely to delay menstruation does not provide reliable contraceptive protection during that cycle.
Clinical Considerations and Pitfalls
Pre-Treatment Assessment
Before prescribing Provera, pregnancy must be excluded with a urine or serum β-hCG test, as fetal exposure may lead to low birth weight and minor birth defects if taken during the first 4 months of pregnancy. 1, 5 Provera should not be used as a pregnancy test. 1
Rule out undiagnosed abnormal genital bleeding, as this is an absolute contraindication requiring diagnostic evaluation before any hormonal therapy. 1
Common Side Effects
Expected side effects of Provera include breakthrough bleeding, spotting, irregular periods, amenorrhea, breast tenderness, headaches, nervousness, dizziness, depression, nausea, bloating, weight gain, and fluid retention. 1
Serious Adverse Events Requiring Immediate Evaluation
Patients should seek immediate medical attention for new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden severe headaches, severe chest or leg pain with or without shortness of breath, memory loss, or confusion. 1
Long-Term Use Concerns
Prolonged use of medroxyprogesterone acetate (particularly depot formulations) may be associated with reversible reduction in bone density related to suppression of endogenous estrogen production. 6 However, this is primarily a concern with depot medroxyprogesterone acetate (DMPA) given every 3 months, not short-term oral use for menstrual delay. 4
Recent data suggest a potential increased risk of meningioma with depot medroxyprogesterone acetate, particularly with exposures longer than 4 years or when started at ages older than 31 years, though the number needed to harm is high (1,152 patients). 7 This risk appears confined to long-term depot use rather than short-term oral administration for menstrual manipulation.
Drug Interactions
Some medications may affect how Provera works, and Provera may affect how other medicines work; patients should disclose all prescription and nonprescription medicines, vitamins, and herbal supplements. 1
Follow-Up and Monitoring
Patients should be counseled to return at any time to discuss questions or concerns, though routine follow-up visits are not required for short-term use. 4 The lowest effective dose should be used, and patients should be re-evaluated periodically (every 3–6 months for ongoing use) to determine if treatment is still necessary. 1